The ‘delivery challenge’ has limited the number of diseases for which RNA therapies have been successfully created
PYC combines existing RNA drug design technology with its proprietary drug delivery platform to create next generation RNA therapeutics
PYC's delivery platform is used to assist the RNA drug reach its target inside the target cell
PYC’s non-viral drug delivery platform and scalable delivery technology addresses the fundamental challenge of RNA drugs – sufficient delivery to the target cell.
Solving this challenge extends the reach of RNA therapies to new disease indications.
PYC’s PPMO is ~100-fold more effective at reaching the target cell in vivo than ‘naked’ 2’MOE RNA drugs